Immune checkpoint inhibitor-associated sick sinus syndrome and cardiogenic shock

被引:0
作者
Kitano, Masatake [1 ]
Yomota, Makiko [1 ]
Ito, Kansuke [2 ]
Hosomi, Yukio [1 ]
机构
[1] Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Thorac Oncol & Resp Med, 3-18-22 Honkomagome,Bunkyo Ku, Tokyo 1138677, Japan
[2] Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Cardiol, 3-18-22 Honkomagome,Bunkyo Ku, Tokyo 1138677, Japan
来源
INTERNATIONAL CANCER CONFERENCE JOURNAL | 2024年 / 13卷 / 04期
关键词
Immune checkpoint inhibitor; Immune-related adverse events; Sick sinus syndrome; Cardiogenic shock; Pacemaker implantation; NIVOLUMAB; OUTCOMES;
D O I
10.1007/s13691-024-00718-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Immune checkpoint inhibitors (ICI) represent a major advance in the treatment of cancer. Most studies of ICI have underestimated their cardiotoxicity; however, an increasing number of cases of cardiotoxicity are being reported. Herein we discussed a 67-year-old, male, Japanese patient who presented with cardiogenic shock accompanied by sick sinus syndrome 4 days into his second course of ipilimumab plus nivolumab combination therapy. A temporary transvenous pacemaker was subsequently placed, and a permanent pacemaker was implanted for persistent, symptomatic, intermittent bradycardia. The permanent implantation of the pacemaker improved his symptoms and allowed him to continue his ICI therapy.
引用
收藏
页码:504 / 509
页数:6
相关论文
empty
未找到相关数据